NCT04309578 2024-02-28
A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC
Asan Medical Center
Phase 2 Unknown
Clinical Trials
276 trialsNCT03500380 2024-02-20
A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases
RemeGen Co., Ltd.
Phase 2/3 Unknown
NCT03818685 2024-02-12
BreastImmune03
Centre Leon Berard
Phase 2 Unknown
NCT04844385 2024-02-09
Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT05980689 2024-02-07
Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT04400695 2024-01-24
A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
RemeGen Co., Ltd.
Phase 3 Unknown
NCT06202014 2024-01-19
Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT05859477 2024-01-02
NIVOFGFR2
Kidney Cancer Research Bureau
Phase 2 Unknown
NCT04395989 2023-12-22
FUTURE-SUPER
Fudan University
Phase 2 Unknown
NCT05578287 2023-12-07
DETECT
Sun Yat-sen University
Phase 2 Unknown
NCT06156761 2023-12-05
Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase NA Unknown
NCT03729687 2023-11-30
LARCT-US
Uppsala University
Phase 2 Unknown
NCT05262335 2023-11-28
ALTER-G-001
Ruijin Hospital
Phase 2 Unknown
NCT05512520 2023-11-18
EC-CRT-003
Sun Yat-sen University
Phase 2 Unknown
NCT04310176 2023-11-13
REVOLUTION
National Cancer Institute, Naples
Phase 2 Unknown
NCT05307198 2023-10-10
RAIC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT00958737 2023-09-29
IDEA
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 3 Unknown
NCT03691051 2023-09-25
A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT06015100 2023-08-29
Efficacy and Safety of Inetetamab Plus Pyrotiniband and Capecitabine in HER2-positive Metastatic Breast Cancer Patients With or Without Brain Metastasis
Xi'an International Medical Center Hospital
Phase NA Unknown
NCT04262804 2023-08-22
A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC
Zai Lab (Hong Kong), Ltd.
Phase 2 Unknown
NCT05415917 2023-08-22
Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy
Rutgers, The State University of New Jersey
Phase 2 Unknown
NCT04262687 2023-08-18
POCHI
Federation Francophone de Cancerologie Digestive
Phase 2 Unknown
NCT04156698 2023-08-09
Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
Phase 2 Unknown
NCT05974059 2023-08-03
Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04262635 2023-08-02
C-CLASSIC
Sun Yat-sen University
Phase 3 Unknown
NCT03950154 2023-08-01
Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT05845138 2023-08-01
A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Unknown
NCT05964543 2023-07-28
The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors
QureBio Ltd.
Phase 1/2 Unknown
NCT05965154 2023-07-28
Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown
NCT04304352 2023-06-28
VEX
European Institute of Oncology
Phase 2 Unknown
NCT02560298 2023-06-22
InterAACT
Eastern Cooperative Oncology Group
Phase 2 Unknown
NCT04072107 2023-06-18
EP-STAR
Sun Yat-sen University
Phase 2 Unknown
NCT05799820 2023-05-25
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
Qilu Pharmaceutical Co., Ltd.
Phase 2 Unknown
NCT02288195 2023-05-12
CONVERT: Neoadjuvant Chemotherapy Alone Versus Preoperative Chemoradiation for Locally Advanced Rectal Cancer Patients
Sun Yat-sen University
Phase 3 Unknown
NCT05833919 2023-04-27
Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients
Consorzio Oncotech
Phase 2 Unknown
NCT03613181 2023-04-24
ANGLeD
Angiochem Inc
Phase 3 Unknown
NCT04522284 2023-03-29
PRECISE CURATE.AI Pilot Clinical Trial
National University Hospital, Singapore
Phase 1/2 Unknown
NCT01898104 2023-03-24
V-shoRT-R3
National Cancer Institute, Naples
Phase 1/2 Unknown
NCT04942899 2023-03-01
Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer
Assiut University
Phase 2 Unknown
NCT05549466 2023-02-08
Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC
Sun Yat-sen University
Phase 2 Unknown
NCT05659290 2023-01-06
Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT03775525 2022-12-23
GEN602
Genzada Pharmaceuticals USA, Inc.
Phase 1 Unknown
NCT04001621 2022-12-08
Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer
Fudan University
Phase 2 Unknown
NCT05608785 2022-11-08
Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes
Henan Cancer Hospital
Phase 1/2 Unknown
NCT05390476 2022-11-04
Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial
Sun Yat-sen University
Phase 2 Unknown
NCT05411380 2022-11-04
Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.
Sun Yat-sen University
Phase 2 Unknown
NCT02973737 2022-10-25
A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT05566743 2022-10-04
A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas
Menoufia University
Phase 2 Unknown
NCT05545436 2022-09-22
Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2 Unknown
NCT04782804 2022-08-18
Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence
Fudan University
Phase 1/2 Unknown